To Investigate the Effect of PEMF for Knee OA Patients
Key facts
- Who runs it
- Chinese University of Hong Kong
- Where
- Hong Kong1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 60 people enrolled
- Started
- 5 Jul 2022
- Ended
- 31 Aug 2024
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- PEMF treatment
- Placebo treatment
- Record updated
- 6 May 2025
Who can take part
- Age
- 50 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 16 criteriaShow less
Who can take part
- Primary osteoarthritis of knee
- VAS score ≥ 4
- Grade 2 and 3 osteoarthritis (Kellgren-Lawrence criteria)
- No alleviation of symptoms after ≥ 3 months of nonsurgical treatment
- No acute knee injuries in both limbs in the past 3 months
- No muscle strain in both limbs in the past 3 months
- Voluntarily agreed to participate and signed the informed consent form
Who cannot take part
- Patient with a pacemaker, an implantable defibrillator, neurosurgical clips, a neurostimulator, cochlear implant, a stent, an insulin pump
- Skin diseases around the target knee joint
- Inflammatory joint disease (e.g., rheumatic inflammation)
- Infectious joint disease (e.g., septic arthritis)
- Severe pain in other areas affects the diagnosis of function and symptoms of knee joints
- Injection in target knee within 3 months of enrolment
- Pregnant or breastfeeding
- Physical inability to undertake testing procedures
- Inability to give informed consent
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Health care costs are increasing alarmingly, which will impose an overwhelming economic burden to an aging society like that of Hong Kong. For example, degenerative musculoskeletal disorders such as osteoarthritis (OA) present a grand challenge with its high prevalence (>40% in the elderly suffered from knee OA). Knee osteoarthritis (OA) is the most common form of arthritis, and around 2 million population worldwide suffer from this disorder. OA is a debilitating progressive disease with typical pathological progress such as cartilage degeneration, inflammation, joint width narrowing and developing osteophytes. The main system of knee OA is acute pain leading to loss of mobility. There is no effective treatment to cure or stop the progression of OA. For now, the main method is to alleviate the pain and symptoms, including control weight, exercise, physical treatment and intake of NSAIDs/ paracetamol.
Read full original descriptionShow less
Pulsed electromagnetic field (PEMF) treatment has shown to enhance cell activity related to tissue healing, delay bone and cartilage degeneration and give beneficial effects such as relief in pain, anti-inflammation and reduce swelling. In clinic, PEMF treatment has been reported to be safe, and has been proved to reduce the usage of NSAIDs and pain in patients with knee OA.
This study aims to investigate the effectiveness of PEMF therapy on for patients with knee OA.
The 2 groups in the trial
- Mild-to-moderate Knee OA PEMF TreatmentTreatment being tested
Patients with Mild-to-moderate Knee OA will accept PEMF treatment
Treatment: PEMF treatment
- Mild-to-moderate Knee OA Placebo TreatmentPlacebo, for comparison
Patients with Mild-to-moderate Knee OA will accept placebo treatment
Treatment: Placebo treatment
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Pulsed Electromagnetic Fields (PEMF) in Knee Osteoarthritis: a Double-blind, Placebo-controlled, Randomised Clinical Trial
- Publications
- Pulsed Electromagnetic Field Therapy for Mild-to-Moderate Knee Osteoarthritis: A Double-Blind, Randomized, Placebo-Controlled Clinical Trial.Journal of cachexia, sarcopenia and muscle, 2026
- Record updated
- 6 May 2025